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Terahertz reflectometry imaging 
for low and high grade gliomas
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Gross total resection (GTR) of glioma is critical for improving the survival rate of glioma patients. 
One of the greatest challenges for achieving GTR is the difficulty in discriminating low grade tumor 
or peritumor regions that have an intact blood brain barrier (BBB) from normal brain tissues and 
delineating glioma margins during surgery. Here we present a highly sensitive, label-free terahertz 
reflectometry imaging (TRI) that overcomes current key limitations for intraoperative detection of 
World Health Organization (WHO) grade II (low grade), and grade III and IV (high grade) gliomas. 
We demonstrate that TRI provides tumor discrimination and delineation of tumor margins in brain 
tissues with high sensitivity on the basis of Hematoxylin and eosin (H&E) stained image. TRI may help 
neurosurgeons to remove gliomas completely by providing visualization of tumor margins in WHO 
grade II, III, and IV gliomas without contrast agents, and hence, improve patient outcomes.
Around 28% of all primary brain tumors and 80% of primary malignant brain tumors are gliomas1. Many malig-
nant glioma types, especially glioblastoma (GBM), have a poor prognosis even though aggressive therapy includ-
ing surgery, radiotherapy, and chemotherapy are performed2. Several prognostic factors for better outcomes 
in glioma patients have been reported, which include age, genetic mutations, achievement of gross total resec-
tion (GTR)3–6. Among these factors, achievement of GTR was found to be crucial for the better prognosis7–10. 
Incomplete resection, even in low grade gliomas, leads to higher probability of recurrence and shorter survival 
by residual tumor11,12. The most serious obstacle to achieving GTR is the difficulty in tumor discrimination and 
margin delineation during surgery. Various techniques have been employed to distinguish gliomas and demar-
cate accurate tumor margins. For example, a neuronavigation system based on preoperative magnetic resonance 
imaging (MRI) has been widely used to perform glioma surgery13–15. However, the method often fails to trace 
tumor margins during the operation due to brain-shift13,16, and consequently GTR rates are lower as compared 
with advanced methods such as intraoperative MRI17 and fluorescence imaging with 5-aminolevulinic acid 
(5-ALA)10,18 or fluorescein sodium8. Intraoperative MRI has been used to increase GTR rates, but involves long 
operation time owing to additional scanning and requires repetitive administration of contrast media such as 
gadolinium (Gd) chelates19. Fluorescence-guided surgery with 5-ALA is a recently adopted method to enable 
real-time tumor margin discrimination in surgery by means of emission of protoporphyrin IX (ppIX) fluores-
cence induced by 5-ALA10. However, low grade and some grade III glioma tissues do not exhibit visible ppIX 
fluorescence due to an intact blood brain barrier (BBB) or high ferrochelatase activity. Therefore, this method 
has not been utilized for World Health Organization (WHO) grade II and III glioma surgeries20. Recently, some 
investigators introduced surface enhanced Raman scattering (SERS) imaging and photoacoustic imaging with 
contrast media for high grade glioma surgery21. However, these methods also do not enable detection of low grade 
and some grade III gliomas, as an intact BBB prevents such contrast media from extravasating into the tumor. 
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Most up-to-date intraoperative technologies to discriminate and delineate tumor margins for glioma surgery have 
been suffered from and limited by the followings: (i) brain-shift, (ii) use of contrast agent, or (iii) low sensitivity 
for low grade glioma and WHO grade III glioma with intact BBB.
Here we present a terahertz reflectometry imaging (TRI) method to tackle the aforementioned limitations. 
TRI has been applied to brain diseases and cancer diagnosis for over a decade, since it is highly sensitive to water 
molecules and tissue components22–28. First of all, TRI intrinsically avoids the brain-shift problems of the neu-
ronavigation system because real-time measurement can be performed with portable TRI devices29,30. Secondly 
TRI, a label-free imaging method, does not use contrast media. Lastly, TRI is capable of detecting low grade and 
grade III tumor with intact BBB for the successful GTR.
Results
TRI of ex vivo human GBM tumorsphere (TS) bearing mouse. We conducted TRI of ex vivo GBM 
bearing mouse samples (n = 4). It has been noted that as malignant gliomas grow, they are manifested by a 
significant reduction of the total lipids and increase in water content31,32. We therefore hypothesized that TRI 
may be capable of discriminating glioma from normal brain owing to its high sensitivity to water and lipid con-
tent23,33,34. We used an orthotopic xenograft model in which enhanced green fluorescent protein (eGFP)-trans-
fected human GBM TS (eGFP+GSC-11) were implanted into BALB/c nude mice (Materials and Methods). The 
tumor growth was screened with a 9.4T animal MRI, and the mice were sacrificed at 42 days after injection of 
tumor cells (Fig. 1a and Materials and Methods). 5-ALA solution was injected 2 h before the sacrifice to obtain 
ppIX fluorescence images, which were compared with TRI images as an existing advanced intraoperative tumor 
discrimination method. The extracted brain tumor samples were placed on a quartz sample window, and we 
sequentially obtained white light, TRI, optical coherence tomography (OCT), ppIX fluorescence, GFP fluores-
cence and Hematoxylin and eosin (H&E) stained images (Materials and Methods). The tumors were invisible in 
white light images (Fig. 1b), whereas they were clearly visualized in GFP fluorescence and H&E stained images 
Figure 1. Tumor discrimination of enhanced green fluorescent protein (eGFP)-transfected human GBM 
tumorsphere (TS) (eGFP+ GSC-11) tumor-bearing mice (n = 4) with TRI and multi-modality imaging. 
(a) Axial T2-weighted MRI images in living mouse for validation of tumor growth. (b) White light images of 
the excised brain samples. The tumors were invisible in the white light images as in human malignant gliomas. 
(c) GFP fluorescence images. (d) Hematoxylin and eosin (H&E) stained image. Both modalities were used for 
visualization of tumor regions. (e) Optical coherence tomography (OCT) images. These images provide detailed 
information through the high resolution anatomical structures. Although some regions with reduced scattering 
may correspond to the tumor region, it is not common feature. (f) TRI images with peak-to-peak amplitude of 
time-domain signals. Relatively high intensity regions (red) in TRI images are well correlated with real tumor 
regions that are observed in GFP and H&E stained images. We did not determine the precise threshold value in 
this preclinical experiment. (g) 5-ALA-induced ppIX fluorescence images. TRI images showed tumor regions 
more precisely than ppIX fluorescence images. Strong fluorescence in the center of the ppIX images of the 
mouse brains is emitted not from tumor but the ventricles.
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(Fig. 1c,d). OCT images offered detailed anatomical information of brain tissues, but distinct tumor regions 
could not be visualized (Fig. 1e). The TRI images, in contrast, presented tumor regions with high terahertz (THz) 
reflection signals compared with normal brain regions (Fig. 1f). The high intensity regions (red, Fig. 1f) in TRI 
images were better correlated with tumor regions in GFP fluorescence, and H&E stained images, as compared 
with ppIX images (Fig. 1g). Especially in mouse #4, the fluorescence of tumor regions was not positive in the 
ppIX fluorescence image due to weak tumor development, which was inferred from the H&E stained image and 
the low intensity of the GFP fluorescence image; however, the tumor region was well visualized in the TRI image 
(bottom of Fig. 1).
TRI for WHO grade II, III, and IV glioma specimens obtained from patients. We performed TRI 
for human glioma specimens to validate its capability of tumor discrimination from normal brain tissues. Glioma 
specimens were obtained from surgeries of 14 glioma patients. Tumor grades of the specimen were confirmed as 
four grade IV, four grade III, and six grade II gliomas by routine pathological examinations (Table 1, Materials 
and Methods). A neuropathologist diagnosed these tumors according to WHO classification35. All TRI images 
were characterized by the time-domain THz reflectometry system.
For a quantitative analysis, we defined a terahertz parameter (TP) as spectrum amplitude ratio at 0.5-THz 
from the region of interest (ROI). The 0.5-THz is a suitable frequency for biomedical imaging in THz regime36. 
We measured spectrum amplitudes at 0.5-THz in tumor (n = 14), normal gray matter (n = 4), and normal white 
matter (n = 4) specimens, and then these were normalized to spectrum amplitude at 0.5-THz from each of water 
reference signals (Fig. 2a, Supplementary Fig. 1). We sampled the normal gray and white matter tissues located 
in the surgical trajectory to determine the tumor threshold values from the tumor-free specimens. Results were 
presented as means ± SD (standard deviations), as appropriate. Data were analyzed using SPSS for Windows, 
Version 12.0 (SPSS Inc., Chicago, IL, USA). Kruskal Wallis test demonstrated that there was a pair having a dif-
ference in three groups. Then, the post-hoc test performed by Mann-Whitney test verified the other pair of values 
the differences in Bonferroni’s method. (Significance level of Bonferroni’s method is 5%/verification number). 
P values of each tumor, and normal gray and white matters are 0.001. The TP amplitude was 0.8104 AU ± 0.0219 
(mean ± standard deviation [S.D.]) in normal gray matter and 0.7114 AU ± 0.0246 in normal white matter; the 
value in the gray matter was greater than that of the white matter, which may result from the intrinsic difference 
in their water and lipid contents (Fig. 2b)37. We determined two threshold TP values to discriminate tumor from 
normal brain tissues. The threshold value 1 (TH1) was set to 0.8542 AU, which was determined by mean + 2 S.D. 
of normal gray matter (dashed red line in Fig. 2b). The red regions denote regions exceeding the TH1 values that 
correspond to either high grade glioma or a dense tumor region of low grade glioma (Fig. 2a–d). Meanwhile, 
some regions with TP values smaller than TH1 were pathologically confirmed as grade II gliomas infiltrating 
into the white matter. It was speculated that when the tumor cells infiltrated to peripheral white matter around 
dense tumor, the water and lipid contents of diffused tumor region may become similar or lower than that of 
normal gray matter. The threshold value 2 (TH2) was thus set to be 0.7852 AU, which corresponds to mean + 3 
S.D. of normal white matter (dashed green line in Fig. 2b). The green indicates regions in which TPs were smaller 
than TH1 and larger than TH2 (Fig. 2c-F), corresponding to lower cellularity tumor region than the red regions 
(Fig. 2c-D,G), even though these green and red regions (Fig. 2c-C–G) represented WHO grade II gliomas his-
tologically. Our results indicate that the green regions in TRI images may represent either low cellularity tumors 
and diffuse tumors or normal gray matter. Nonetheless, neurosurgeons can judge whether the surgical region is 
gray matter or white matter based on the information from the surgical microscope, their anatomical knowledge, 
preoperative MRI and neuronavigation. Therefore, the green region in TRI images would provide useful infor-
mation to neurosurgeons about low grade or diffused tumor regions in surgery. It is worth noting that low grade 
Case Age Sex Pathology WHO grade 5-ALA IDH1 MGMT 1p/19q co-deletion Ki-67 L.I.
1 57 F Glioblastoma IV + Wild Unmethylated No 50%
2 55 M Glioblastoma IV + Wild Methylated No 5–7%
3 67 M Glioblastoma IV + Wild Methylated Yes 15–20%
4 62 F Glioblastoma IV + Wild Unmethylated No 15–20%
5 46 M Anaplastic oligodendroglioma III + Mutant Methylated No 3–4%
6 34 F Mixed oligoastrocytoma II NA Mutant Unmethylated No 3–4%
7 51 F Oligodendroglioma II NA Mutant Methylated Yes 3–4%
8 40 F Diffuse astrocytoma II NA Wild Unmethylated No 2–3%
9 56 F Anaplastic astrocytoma III + Wild Unmethylated No 5–6%
10 41 F Anaplastic astrocytoma III − Wild Unmethylated No 50%
11 36 M Anaplastic astrocytoma III NA Mutant Methylated Yes 20–25%
12 51 F Oligoastrocytoma II NA Mutant Methylated No 2–3%
13 38 M Oligoastrocytoma II NA Mutant Unmethylated No 5%
14 41 M Oligodendroglioma II NA Mutant Methylated Yes 3–4%
Table 1.  Summary of patient pathological information. WHO: World Health Organization; 5-ALA: 
5-aminolevulinic acid; IDH1: isocitrate dehydrogenase 1; MGMT: O6-methylguanine-methyltransferase; 
1p/19q: chromosomal co-deletions that are characteristic of oligodendrogliomas; Ki-67 L.I.: labeling index 
associated with proliferation; NA: not available.
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gliomas, where ppIX fluorescence has been scarcely expressed, could be well discriminated by TRI. Although the 
four tumor specimens including ROIs B-E in Fig. 2c were obtained from the same patient, 5-ALA-induced ppIX 
fluorescence was only expressed at specimens including ROIs B and C, but not in other specimens; in contrast, all 
tumors were discriminated in TRI images (Fig. 2c–d). We assume that our TRI image results reflect a composi-
tional change associated with increased water content and decreased lipid content and this change accompanied 
not only high grade but also low grade gliomas32,38. As a result, we could find the presence of tumor in all cases 
by TRI images.
We then validated the tumor margin delineation ability of TRI. The wavelength of terahertz electromagnetic 
waves is a few hundred-μ m, so TRI may be more suitable as a macroscopic imaging tool of gliomas. While TRI 
may not be able to delineate tumor margin at the cellular level, it has the potential to macroscopically delineate 
foci-glioma margins. Indeed, our macroscopic delineation of the tumor margins were correlated with the patho-
logically determined tumor margins with the H&E stained image. Red and green tumor regions over TH1 and 
TH2 in the TRI image of low grade glioma specimen (case 6) were well correlated with the tumor margin patho-
logically determined with the H&E stained image (Fig. 3a–c). However, a few tumor cells existed outside of the 
Figure 2. Discrimination of low and high grade of human gliomas with TRI. (a) Terahertz parameter 
(TP) values from regions of interest (ROIs) in tumors (n = 14), normal gray matters (n = 4), and normal 
white matters (n = 4). (b) Quantification of threshold value 1 (TH1) and TH2 (dashed red and green lines, 
respectively) for tumor discrimination using the data shown in (a). Data represent mean ± SD. ***P < 0.001 
(Kruskal-Wallis test.) Representative cases of grade IV, III and II gliomas, characterized by (c) TRI images and 
(d) H&E stained image. Red regions indicate regions with TP value over TH1. The capitals A–G shown in  
(d) correspond to the ROIs in (c).
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margin of the foci-tumor region, and the diffused tumor cells were confirmed in an immunochemistry stained 
image (isocitrate dehydrogenase 1 [IDH1, 1/80, clone H09, Dianova, Germany] stain, Materials and Methods) 
and not in a H&E stained image (Fig. 3c–f). The precise tumor margins determined with the immunochemistry 
stained image was found to be further extended than those determined with the TRI image and the H&E image 
(Fig. 3g). Therefore, when a neurosurgeon practically uses this method during glioma surgery, the neurosurgeon 
would need to apply safety margin that could be determined by further investigations or other complementary 
microscopic imaging tools to complete the glioma resection.
TRI of in vivo live mouse tumor model. Finally, we assessed TRI for in vivo tumor detection in a living 
mouse with eGFP+GSC-11 cell xenotransplantation (n = 1). We tracked the tumor growth with 9.4T MRI and 
GFP fluorescence imaging (Fig. 4a,b). After the tumor had grown to the outer surface of brain, we made a cranial 
window and exposed the brain tumor to obtain the TRI image (Supplementary Fig. 2). The tumor showed a dis-
tinctively high intensity signal (red) that was well discriminated from adjacent normal brain tissue in the in vivo 
TRI image (blue and black arrows in Fig. 4c,d). We re-confirmed the tumor detection after the whole brain was 
extracted from the mouse. The high intensity regions in TRI image of extracted brain surface corresponded well 
to the tumor regions that were later confirmed by GFP fluorescence imaging (Fig. 4e–g).
Discussion
We describe a highly sensitive TRI for low and high grade glioma identification without exogenous contrast 
agents. TRI is an imaging technique, implementable to the biomedical field. Because TRI signal is affected by the 
molecular dynamics of water and the differences in the refractive indices between water and lipids, the resultant 
images reflect high sensitivity to water and lipid content in tissues33,39. Glioma is characterized by an increased 
level of water and smaller lipid content in contrast to the adjacent normal brain31,32. Therefore, TRI may serve as 
a high-sensitivity detector for glioma, allowing neurosurgeons to ‘see’ tumor regions without the use of contrast 
agents during glioma surgery. Several papers reported on the possibility of glioma detection using TRI23,40,41. 
However they used only fresh rat or paraffin-embedded samples. In this paper, we performed TRI imaging in 
not only fresh mouse samples but also fresh human specimens. We further carried out in vivo TRI imaging of a 
tumor-bearing mouse model. Through the experiments, we validated the feasibility of TRI for glioma detection 
with preclinical, clinical and in vivo settings in only an article.
TRI exhibits distinct advantages compared with conventional intraoperative surgical methods. Firstly, TRI, 
in a form of handheld device, would be intrinsically obviated from brain-shift challenges that surgeons face fre-
quently in using the brain neuronavigation system. Handheld TRI devices have been already developed29,30, so 
the neurosurgeons could utilize these tools to locate tumors during operation. Secondly, this method has the 
potential to provide a real-time display for the tumor detection at surgery42. Thirdly, TRI is a label-free method, 
so it is unrestrained from the various adverse effects of contrast agent: photo-bleaching, restricted photo retention 
time, patient hypersensitivity to light at ppIX fluorescence-guided surgery method with 5-ALA, and the adverse 
effects produced by repeated gadolinium contrast administration at intraoperative MRI19. Finally, this method 
Figure 3. Delineation of tumor margin with TRI. (a) TRI image of a WHO grade II glioma specimen (case 6). 
The red and green regions denote tumor regions exceeding TH1 and TH2. The graph below TRI image shows 
the display for terahertz parameter value along the dashed line A and B. The green region on right of specimen is 
not tumor because the region is located in gray matter. (b) White light image of the specimen. (c) Tumor margins 
(yellow dashed line) determined by H&E stained image. The result agreed well to the tumor margin detected by TRI 
image. (d) Magnified H&E image (x12.5) of the black dashed box region in (c). (e) A further magnified image (x40) 
of black dashed box region in d, in which tumor cells could not be identified. (f) However, immunohistochemistry 
showed the presence of IDH1 mutated cells (brown) on the same region of (e), which have been known to be 
indicated glioma cells. A further magnified immunohistochemistry image (x400) of some region in (e). (g) Based 
on the IDH1 mutation stained image, the tumor margins (blue dots) should be re-delineated beyond the margins 
determined by H&E stained image.
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could discriminate not only high grade gliomas but also low grade gliomas from normal brain tissues, whereas 
ppIX fluorescence imaging is only effective in high-grade gliomas.
Recent advances in Raman spectroscopy made it possible to discriminate high and low grade gliomas with 
a sensitivity and a specificity of 93% and 91% respectively43,44. Raman methods also use the intrinsic optical 
properties of tissues to characterize the decreased lipid content in gliomas. Therefore, the results from the Raman 
technique could indirectly imply TRI’s high feasibility in the clinical glioma surgery application.
Though Raman imaging has remarkable capability to detect gliomas, it has several obstacles to practically be 
employed in glioma surgery such as low signal to noise ratio and long measurement time. It is difficult to compare 
TRI directly with Raman imaging, because there are differences in operating principles and implementations. 
With regard to spatial resolution, TRI is generally macroscopic, whereas Raman imaging is microscopic24,44,45. 
These features may be combined to provide complementary information for the complete resection of gliomas. 
For example, neurosurgeons may preferentially remove most of the glioma through TRI-validated images where 
the macroscopic tumor margins are visualized, and then they can completely remove residual glioma tissue in the 
periphery of the tumor through Raman-validated images where diffusely invasive brain cancer cells are identified 
at cellular resolution.
The penetration depth of THz waves in tissues is rather limited (generally under 500-μ m) due to the high 
absorption by water46. As such, TRI could detect tumor only when the tumor is exposed on the outer surface of 
the brain. However, we do not consider this as a serious limitation because ppIX fluorescence-guided surgery is 
also limited by a short penetration depth but is very helpful to neurosurgeons.
In some regions of our three human glioma cases (cases 8, 11 and 13), false-positives over TH1 were identified 
although the regions did not possess tumor tissue on histological examination. High-reflection THz signals larger 
than the TH1 should be considered abnormal despite scarce or absent tumor cells. Further investigation on this 
observation will be performed with a larger set of clinical data. As previously mentioned, TRI is a macroscopic 
method, so diffused tumor or peripheral foci-tumor may be expressed as low-signal regions below TH2. This 
limitation may be overcome by simultaneous use of TRI with a complementary microscopic method such as 
Raman imaging.
Today, neurosurgeons mobilize various intraoperative technologies such as the neuronavigation system, intra-
operative MRI, 5-ALA-induced ppIX fluorescence imaging, and ultrasonic systems for complete tumor resection. 
Our TRI method enables the neurosurgeon to detect during surgery not only high grade gliomas, but also low 
grade gliomas with intact BBB involving increased water and decreased lipid content. In the foreseeable future, 
TRI can mitigate the bottleneck of incomplete tumor resection rate in low grade gliomas that are underestimated 
by ppIX fluorescence imaging. We expect this method will be able to substantially contribute to successful glioma 
resections and lead to better outcomes for glioma patients in the future.
Materials and Methods
Study design. Conventional imaging methods for glioma surgery have been limited by the following: 
(i) brain-shift, (ii) use of contrast agent, or (iii) low sensitivity to low grade glioma. The main aim of this study was 
to introduce and demonstrate the potential feasibility of TRI for glioma surgery that enables to overcome current 
key limitations for intraoperative detection of high and low grade gliomas. It has been known that malignant 
Figure 4. In vivo tumor detection in a mouse via TRI. (a) T2-weighted coronal MRI image. (b) In vivo 
GFP fluorescence image. The presence of tumor was screened by the MRI and fluorescence images. Yellow-
orange arrowheads indicate the assumed tumor region. The in vivo experiment was performed after the tumor 
developed to the brain surface. (c) White light image of exposed brain tumor that was in contact with the quartz 
window. Yellow dashed box indicates region of measured TRI image. (d) In vivo peak-to-peak TRI image. 
Tumor regions (blue arrow) were well discriminated from normal brain regions (black arrow) in the live animal. 
(e–g) White light, TRI, and GFP fluorescence images of extracted whole brain, respectively. The gross tumor 
regions, determined by each image (blue arrowheads), were well discriminated in the TRI image and even in the 
white light image (violet arrow). The tumor region in GFP fluorescence image (g) seems to be broader than that 
in THz image (f). The discrepancy may be accounted for by that GFP fluorescence image results in part from the 
diffusive fluorescence signal from the tumors deep in the tissue (Supplementary Figs 3 and 4).
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gliomas are manifested by a significant reduction of the total lipids and increase in water content. We therefore 
hypothesized that TRI may be capable of discriminating glioma from normal brain due to its high sensitivity 
to water and lipid content. First, we conducted preclinical experiments with ex vivo xenotransplantation brain 
tumor models (n = 4) to verify our hypothesis. We compared TRI images with multi-modality images including 
standard H&E images. Next, we evaluated TRI of fresh WHO grade II, III, and IV glioma specimens obtained 
from human patients (n = 14). Finally, we demonstrated that TRI is a viable technique for in vivo glioma detection 
using an in vivo xenotransplantation brain tumor model (n = 1).
Lentiviral vector transduction and expression. Green fluorescent protein (GFP) stably expressing 
GSC11 cells (GSC11-GFP) were generated by growing GSC11 cells in complete medium and then applying 
GFP-expressing lentiviral supernatants. Polybrene (Sigma, Dorset, UK) was added to a final concentration of 
8 μ g/ml and incubated with cells for 18 h. After infection, the cells were placed in fresh growth medium and cul-
tured in a standard manner. Cells were treated with 1 mg/ml puromycin (Life Technologies Korea, Seoul, Republic 
of Korea) to eliminate uninfected cells and generate stable GSC11-GFP. GSC11-GFP was isolated for use in fur-
ther experiments by fluorescence activated cell sorting (FACS).
Mouse care and information. Five-week-old male athymic Balb/c nude mice (Orient Bio, Seongnam-Si, 
Republic of Korea) were used for tumor xenograft experiments. Mice were retained in micro-isolator cages under 
sterile conditions and observed for at least 1 week before study initiation to ensure proper health. Temperature, 
lighting and humidity were controlled centrally. All experimental procedures were carried out in accordance 
with the guidelines Institutional Animal Care and Use Committees (IACUC) which were approved by Yonsei 
University College of Medicine Institutional Animal Care and Use Committee. The mice were anesthetized with 
a solution of Zoletil (30 mg/kg; Virbac Korea, Seoul, Republic of Korea) and xylazine (10 mg/kg; Bayer Korea, 
Seoul, Republic of Korea) delivered intraperitoneally. After the holes were drilled on the mouse skull using a 
26-gauge needle, GSC11-GFP cells (1 × 106) were implanted directly into right frontal lobe of nude mice using 
Hamilton syringe (Dongwoo Science Co., Seoul, Republic of Korea) at the depth of 4.5 mm. Cells were simulta-
neously injected into five mice using a multiple microinfusion syringe pump (Harvard Apparatus, Holliston, MA, 
USA) at a rate of 0.5 μ l/min as previously described47,48.
9.4T animal MRI. We performed in vivo MR imaging experiments with a 9.4T animal MRI instrument with 
a Bruker animal coil (RF SUC 400 1H M-BR-LIN ROAD, Bruker Medical Systems, Germany). The sequence 
parameters were adopted as follows: Echo = 1, TR = 2500 ms, TE = 22.2 ms, FA = 180 deg, TA = Oh2m5s0ms, 
NEX = 1, FOV = 2.50/1.80 cm.
TRI system. To measure the THz signal, we used a homemade THz reflectometric imaging system with pho-
toconductive antennas that were driven by femto-second laser pulses to generate and detect terahertz pulses. We 
used four off-axis parabolic reflectors to collimate and focus THz pulses on ex vivo and in vivo samples and guide 
reflected THz pulses to the detector. The extracted mouse tumor samples and glioma specimens from patients 
were placed on a quartz sample window, and then we mounted the sample window on a computer-controlled 
x-y translation stage which was used to raster scan. The focused beam diameter of THz pulses was 0.8-mm at 
0.5 THz, and THz signals were measured with 20 Hz and 250-μ m scanning resolution. A more detailed descrip-
tion is presented in our previous report45. We obtained TRI images for ex vivo and in vivo mouse samples using 
peak-to-peak amplitude extracted from reflection THz signals.
Combined Optical Coherence Tomography (OCT) and ppIX fluorescence imaging system. Our 
OCT system was implemented based on optical frequency domain imaging as described in [Yun et al. Opt. 
Express, 11: 2953–2963 (2003); Yun et al. Nature Medicine, 12: 1429–1433 (2006)]. A 1.31-μ m wavelength-swept 
laser (SS-1310, Axsun Technologies Inc., USA) was employed as a light source, which provided a sweep range 
of 110 nm, repetition rate of 50 kHz, and average power of ~20 mW. Light from the laser was first directed to a 
90/10 fiber coupler, and 10% of the light was tapped and detected with a fast InGaAs photodetector through a 
narrowband fixed-wavelength filter, serving as a trigger for signal acquisition. The k-clock from the laser was 
directly connected to a digitizer for signal sampling. Ninety percent of the remaining light was directed to the 
OCT interferometer.
In the OCT sample arm, we combined ppIX fluorescence imaging setup to perform a direct comparison of 
the tumor regions measured by TRI and OCT against the regions by ppIX fluorescence imaging. A 405-nm laser 
diode (FL laser) was employed as a fluorescence excitation light source. The light from the laser was combined 
with the 1.3-μ m OCT probe light through the dichroic mirrors DM1 (47267, Edmund Optics, USA) and DM2. 
The combined light was then directed to a specimen through the same galvanometric scanners (GM) and illumi-
nation optics described above. This arrangement enabled both OCT and fluorescence images to share the same 
field of view, facilitating direct image comparison. The beam size of the 405-nm excitation light on the specimen 
plane was measured to be 80 μ m. The backscattered OCT light from the sample was re-coupled to the fiber and 
its interference with reflection from a reference mirror was detected by a high-speed balanced detector (Thorlabs, 
Inc., PDB410C, New Jersey, USA). For the fluorescence signal, the fluorescence emission from the specimen was 
collected by the focusing lens, reflected by the dichroic mirror DM3 (NFD-01-633, Semrock, USA), and subse-
quently detected with a large-area photodetector (PDA100A-EC-Si, Thorlabs, USA) through a lens.
GFP fluorescence imaging. We performed ex vivo fluorescence imaging using green fluorescence protein. 
The fluorescence recovery profiles in eGFP+ GSC-11 tumor-bearing mice were imaged by positioning mice on 
an animal plate, heated to 37 °C, in the IVIS spectrum system (Caliper Life Science, Hopkinton, MA, USA) as 
per the manufacturer’s instructions. Excitation and emission spots were raster-scanned over the selected region 
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of interest (ROI) to generate emission wavelength scans, wavelength of fluorescence were 488 nm and 520 nm 
respectively for ex vivo samples. All data, including whole body and two-dimensional (2D) slice images, were 
calculated using the ROI function of the Analysis Workstation software.
Patient population. Fourteen patients with WHO grade II, III, and IV glioma, including 4 grade IV, 4 
grade III, and 6 grade II patients, treated at our institution between February 2014 and December 2014 were 
included in this study (Table 1). All patients were histologically diagnosed and graded by neuro-pathologists 
according to 2007 WHO classification criteria. Informed consent was provided according to the Declaration 
of Helsinki. All patients provided written informed consent, and the study was approved by the Institutional 
Review Boards of Severance Hospital, Yonsei University College of Medicine. All experiments were conducted 
in accordance with principles expressed in the Declaration of Helsinki or other relevant guidelines and regula-
tions. O-6-methylguanine-DNA methyltransferase (MGMT) promotor methylation and isocitrate dehydroge-
nase (IDH)-1 mutations were assessed by polymerase chain reaction (PCR) and immunohistochemistry (IHC). 
Epidermal growth factor receptor (EGFR) amplification and loss of heterozygosity (LOH) at chromosomes 1p 
and 19q were evaluated by fluorescent in situ hybridization (FISH). P53 and ki-67 were examined by IHC.
IDH1 Immmunohistochemistry (IHC). With a representative section, we performed IHC with a 
VentanaBenchMark XT autostainer (Ventana Medical System, Inc. Tucson, AZ) according to the protocol. The 
antibody used was anti-human IDH1 R132H mouse monoclonal (Clone H09L, 1:80 dilution, Dianova, Hamburg, 
Germany). A neuropathologist (S.H. Kim) reviewed the immunohistochemical and histologic findings without 
information of IDH1 mutation status assessed by other methods. When the cytoplasmic expression of the IDH1 
R132H was identified in glioma cells, we regarded those cases as “mutant” or “positive”.
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